Media & Technology
Superlight Solar, Crowdex, the Parabolic Run on Ascent Solar Technologies, Inc. (OTCMKTS: ASTI)
Ascent Solar Technologies, Inc. (OTCMKTS: ASTI) is making a powerful run up the charts in recent week as the Company completes a change of control with Bernd Förtsch’s Crowdex becoming majority shareholder of ASTI. Since taking control Bernd Fortsch, a well-known German entrepreneur worth hundreds of millions of euros has brought on a top level management team of major international executives including Michael Gilbreth as CFO and Will Clarke as class 2 director. The Company is getting their filings in order looking to up list to fully reporting.
Microcapdaily has been reporting on ASTi for years noting back in 2016 shortly after the Company had been delisted by NASDAQ: ‘OTC speculators love ex big board stocks for their ready liquidity and proven ability to make spectacular moves once on the bb’s and ASTI certainly has potential; this is a company that manufactures battery and solar integrated phone cases designed for Apple and Samsung smartphones that recently announced record revenues as well as a major breakthrough in power-to-weight ratio for its superlight solar modules.”
Ascent Solar Technologies, Inc. (OTCMKTS: ASTI) operating out of Thornton, Ontario, an ISO 9001-2015 certified company is a developer and manufacturer of state-of-the-art, lightweight, and flexible thin-film photovoltaic (PV) modules using flexible substrate materials that are more versatile and rugged than traditional solar panels. Ascent Solar modules were named as one of the top 100 technologies in both 2010 and 2015 by R&D Magazine, and one of TIME Magazine’s 50 best inventions for 2011. The technology represents the cutting edge of flexible power and can be directly integrated into consumer products and off-grid applications, as well as other aerospace applications. Ascent Solar owns a valuable patent portfolio including over 80 granted and pending patents.
The big story on ASTI is the recent change of control via the Crowdex transaction described in 8k’s filed 12/04 and 12/28 whereby Crowdex became majority owner of ASTI. Bernd Förtsch whose net worth is several hundred million Euros is 100% ownder of Crowdex making him the majority shareholder in ASTI. Bernd Förtsch is a German entrepreneur and publisher. He is the founder and owner of the Kulmbach- based Börsenmedien AG, which publishes, among other things, the stock exchange and financial magazines The Shareholder and The Investor. In addition, Bernd Förtsch is founder and owner of Aktionär TV AG and founder of the online broker flatex . Förtsch achieved notoriety above all in the context of the stock market euphoria of the Neuer Markt. Mr. Förtsch is 60,3% owner of TubeSolar AG and he holds stakes in Companies such as BF Holding GmbH, Deposit Solutions GmbH, Flatex AG, the biggest online broker in Europe, valued at 1.2 billion Euros, Flatex Bank AG, Börsenmedien AG, Coreo AG, Fintech Group AG and many more.
ASTI’s award winning thin-film CIGS solar modulest are more flexible, versatile and rugged than traditional solar panels. They use plastic as their substrate rather than glass that’s used by tradition rooftop solar panels. The Company diversified into consumer goods as they could not compete with the low-cost Chinese solar panels in the traditional electricity generating segment.
https://twitter.com/JamesKMagee1/status/1343677727103090688
To Find out the inside Scoop on ASTI Subscribe to Microcapdaily.com Right Now by entering your Email in the box below
Ascent has achieved a major breakthrough in power-to-weight ratio for its superlight solar module, delivering over 1700 watts of power per kilogram, operating at AM0, technically known as the space environment. At this performance, Ascent’s superlight module would weigh 66% less than a comparable PV system using the highest-quality crystalline silicon and with far less design complexity. The elimination of two-thirds of the weight is a critical improvement for satellites, space vehicles and space stations. For space and near-space applications, power-to-weight ratio is a key performance metric. In addition to simplicity, the Company’s modules could dramatically impact cost. Depending on the application, such as low earth orbit all the way to manned flights, including contemplated missions to Mars, the fully burdened cost can be anywhere from thousands of dollars to $1 Million per pound for a space launch. By creating this superior module with the best power-to-weight ratio of any available product, Ascent has enabled entrance into the rapidly growing space and near space markets.
On December 7 ASTI announced new Board of Directors composition and Chief Financial Officer. The Company appointed David Peterson as a Class 3 director to be effective as of December 10, 2020. Mr. Peterson is currently the Manager of Crowdex Investment. Crowdex is the Company’s controlling stockholder through its holdings of the recently issued shares of Series 1A Preferred Stock pursuant to Form 8-K filing on September 30, 2020. ASTI also appointed high level executive Will Clarke as director. Previously, Will directed turnaround initiatives for Best Buy managing a team in procuring material to update 1400 stores and facilities which improved the customer experience and spun negative sales into growth. The whole Board of Directors going forward will have five members comprised of Dr. Amit Kumar, Chairman of the Board, Kim Huntley and Will Clarke as the independent directors, and Victor Lee and Dave Peterson serving as Class 3 directors.
ASTI CEO Victor Lee also brought Michael Gilbreth on board to serve as the Chief Financial Officer of the Company effective October 5, 2020. Mr. Lee continues to serve as Chief Executive Officer and a director of the Company.
ASTI CEO Victor Lee stated: “We will continue our reorganization effort and strengthen our balance sheet and streamline our business model to focus on our core strength in the Tier-1 specialty PV markets with high entry barriers like the space and near-space, aviation (drones), military, 1st Responders and emergency power markets. Great progress has been made in the space and near-space, defense and emergency power market in 2020 despite an extraordinarily difficult year. We are optimistic and look forward to stronger years ahead, as our high-value PV market focus begins to take shape. We look forward to updating our shareholders as we make continued progress.”
$ASTI – …so he Bernd Förtsch just acquired 91.4% of the company, and a friend of him, Johannes Kuhn, another German citizen, bought all the debt notes except one, for $10.5M. The maturity date of this note is in December of 2015, yes, in FIVE years…
— Dr PennyStock (@Dr_PennyStock) December 30, 2020
For More on ASTI Subscribe Right Now!
ASTI is making a powerful run up the charts in recent week as the Company completes a change of control with Bernd Förtsch’s Crowdex becoming majority shareholder of ASTI. Since taking control Bernd Fortsch, a well-known German entrepreneur and leader in the European solar space worth hundreds of millions of euros has brought on a top level management team of major international executives including Michael Gilbreth as CFO and Will Clarke as class 2 director. The Company is getting their filings in order looking to up list to fully reporting. Microcapdaily has been reporting on ASTi for years noting back in 2016 shortly after the Company had been delisted by NASDAQ: ‘OTC speculators love ex big board stocks for their ready liquidity and proven ability to make spectacular moves once on the bb’s and ASTI certainly has potential; this is a company that manufactures battery and solar integrated phone cases designed for Apple and Samsung smartphones that recently announced record revenues as well as a major breakthrough in power-to-weight ratio for its superlight solar modules.” Ascent Solar modules were named as one of the top 100 technologies in both 2010 and 2015 by R&D Magazine, and one of TIME Magazine’s 50 best inventions for 2011. The technology represents the cutting edge of flexible power and can be directly integrated into consumer products and off-grid applications, as well as other aerospace applications. Last year the US Department of Energy (DOE) used Ascent Solar modules for two exclusive development projects. Things are looking up for Ascent as Tesla looks to Solar to power its new gigafactory. We will be updating on ASTI as events unfold so make sure you are subscribed to Microcapdaily so you know what is going on with ASTI.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Disclosure: we hold no position in ASTI either long or short and we have not been compensated for this article.
Enveric Biosciences, Inc. (NASDAQ: ENVB) shares surged 78% this morning upon approval of some fantastic news. The United States Patent and Trademark Office has granted them a notice of allowance for their patent application concerning a groundbreaking chemical compound called EB-373. This compound is being developed to address the treatment of anxiety disorders.
The forthcoming patent, titled “C4-Carbonothioate-Substituted Tryptamine Derivatives and Methods of Using,” encompasses claims for the composition of matter of a family of revolutionary prodrug derivatives of psilocin. Enveric’s lead product candidate, EB-373, stands out among these derivatives. A Notice of Allowance signifies that the USPTO has determined that a patent should be granted based on the submitted application.
To Discover the Inside Scoop on ENVB, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
$ENVB halted up
— Antonio Costa (@ACInvestorBlog) May 18, 2023
Enveric’s commitment to innovation extends beyond EB-373. They have also submitted additional patent applications to the USPTO, exploring psilocin prodrugs with unique crystalline molecular structures. Moreover, they have taken proactive steps to pursue global coverage of the EVM201 and EVM301 Series through companion Patent Cooperation Treaty and non-US national patent applications. Encouragingly, positive International Search Reports and written opinions have been received under the Patent Cooperation Treaty for most of these applications.
$ENVB 💰💰💰💰💰 pic.twitter.com/qCIxiCpF0E
— FonsieTrader (@FonsieTrader) May 18, 2023
Joseph Tucker, Ph.D., Enveric’s director and CEO, underlined the significance of the USPTO’s favorable decision concerning their lead candidate, EB-373. He highlighted the innovative designs of their psilocin prodrugs within the EVM201 series, differentiating them from conventional counterparts like psilocybin. These novel designs hold the potential to deliver more rapid therapeutic effects, precise control, and reduced gastrointestinal side effects. Tucker emphasized that securing a robust intellectual property portfolio for their new chemical entity prodrugs is pivotal to Enveric’s value proposition and integral to their business strategy of developing cutting-edge small-molecule therapeutics to address mental health disorders.
$ENVB 👇this is an important milestone for the company! The price could increase fivefold wit the time imo.
Enveric Biosciences Receives Notice Of Allowance From US Patent And Trademark Office For Novel Prodrug Of Psilocin
— Swingy John (@daytrader_2020) May 18, 2023
We will update you on ENVB when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.
Image by Gino Crescoli from Pixabay
TScan to Receive $30 Million Upfront With Potential Development and Commercial Milestone Payments of Over $500 Million.
Collaboration Brings Together TScan’s Proprietary Target Discovery Platform and Amgen’s Inflammation Therapeutic Expertise and Research Capabilities
Amgen (NASDAQ: AMGN) and TScan Therapeutics, Inc. (NASDAQ: TCRX) today announced a multi-year collaboration that will use TScan’s proprietary target discovery platform, TargetScan, to identify the antigens recognized by T cells in patients with Crohn’s disease.
All things considered, this is among one of the largest deals you’ll see for a micro-cap biopharma company. As many of you know, companies in this sector of this size and scale are typically not profitable – mainly focusing on R&D until their drug or technology is fully approved/commercially viable.
The critical thing to note with this deal between TScan and Amgen is that the cash milestones ensure a cash runway for TCRX, potentially even until they become commercially viable and profitable.
Here’s a breakdown of the press release in layman’s terms, so anyone without background or knowledge in this space can better understand:
Amgen and TScan Therapeutics are teaming up to find new treatments for Crohn’s disease, a chronic condition that causes inflammation in the gut. TScan has a unique platform called TargetScan that can identify the proteins recognized by the immune system in people with the disease. Amgen will use this information to create new drugs to treat Crohn’s disease.
As part of the deal, TScan will get an upfront payment of $30 million from Amgen and could earn more than $500 million if the collaboration is successful. Amgen will have the rights to develop and sell any new drugs from this partnership.
To Discover the Inside Scoop on TCRX, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Both companies will be responsible for their research costs, and Amgen can expand the collaboration to include another condition called ulcerative colitis. This partnership could lead to new and better treatments for people with Crohn’s disease, who currently have limited options for managing their symptoms.
Here are a couple of blurbs from the management team:
“Anti-inflammatory drugs have traditionally been the standard of care for patients suffering from inflammatory bowel disease, but often lack efficacy and durability,” said Raymond Deshaies, Ph.D., senior vice president of Global Research at Amgen. “TScan’s platform provides a best-in-class approach to identify non-conventional drug targets to enable the development of potential first-in-class therapeutics to address unmet medical needs.”
“We’re excited to apply our target discovery platform to the autoimmunity space,” said Gavin MacBeath, Ph.D., acting chief executive officer and chief scientific and operating officer at TScan. “Our TargetScan platform, which we have now extended to identify MHC class II targets of CD4+ T cells, is well-suited for the discovery of antigens targeted by the immune system in inflammatory bowel disease. We look forward to developing the value of our platform both in this partnership with Amgen and in other autoimmune diseases.”
What’s retail saying?
As per usual, with gains of around 135%, you can probably guess that retail is all over it. Investors practically all over the internet keep their eye on the stock for potential entry points utilizing various day trading techniques.
Interestingly, some traders are surprised it managed to trade such massive volumes early intraday. If you look at their chart from the prior months, the average volume was relatively minuscule – sometimes trading as low as 5K shares a day. Compared to the ~27M shares traded at the time of writing, that’s a massive shift.
$TCRX #TCRX nice wake up call watch the break above 5.47 to potential 6.25 test pic.twitter.com/FvoAYEFslG
— APFK_ASIAN PICASSO. (@FLiPTek81) May 9, 2023
$TCRX deserves 1000% 30m upfront 500m contract!
— SHANA (@shanazaman) May 9, 2023
$TCRX ✅✅great earnings 75%gain for me
— Ethio-TradE (@alemcharity) May 9, 2023
$TCRX guess they're not done screwing with people yet. That thing looked dead next thing you know, BAM!
— madaz (@madaznfootballr) May 9, 2023
$LCID massive buyers check orderflow. Count the +ve delta numbers and check sizes. $PLTR $MOBQ $IDEX $CLRO $PYPL $TSLA $FFIE $AMD $TCRX $SOXL $SQQQ $TQQQ $NVAX $PLUG $ENSC $BOIL $XELA $NKLA $CVNA $AAPL pic.twitter.com/d0RaG1xvQl
— Time Traveler Carlssin's Trades (@StockMarketMcro) May 9, 2023
We will update you on TCRX when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening with TCRX.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.
Image by Gerd Altmann from Pixabay
On April 27, 2023, shares of ContraFect Corp (NASDAQ: CFRX) skyrocketed by 125% in pre-market trading, which is quite unusual. Although the surge may be linked to the news from the previous day, it is difficult to determine as there was not much movement on April 26.
However, sometimes it only takes the right attention from investors to create such positive rallies. It is worth noting that $CFRX has a low float of 1.53M, which can lead to extreme volatility and provide retail traders an opportunity to make significant gains.
To Find out the inside Scoop on CFRX Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Summary of latest PR on April 26, 2023
ContraFect Corporation is a clinical-stage biotechnology company developing new treatments for antibiotic-resistant infections. They recently announced that they initiated a Phase 1b/2 study to test the safety, drug disposition, and efficacy of their drug candidate, Exebacase, in patients with chronic prosthetic joint infections (PJI) of the knee. The study is in France and is randomized, double-blind, and placebo-controlled, meaning some patients will receive the drug, while others will receive a placebo. The study will have two parts: Part I will evaluate the drug’s efficacy, safety, and pharmacokinetics at an early six-week time point, while Part II will assess the long-term clinical safety and efficacy of the drug for up to two years. The CEO of ContraFect Corporation is optimistic about the potential of Exebacase to replace the current surgical treatment for chronic PJI, which has not shown significant improvement in clinical outcomes in recent decades.
What are retail traders saying?
https://twitter.com/RealWillTopol/status/1651553835801001986?s=20
$CFRX
Running in Pre Market Almost +100% From PDC— Avid Trader (@RealAvidTrader) April 27, 2023
$CFRX Why LONG? 🔍👁
Premarket long pattern from the system in room
– dilution above $4
– key level $4
– shorts trapped this early morning
– pullback on trend following
– microfloat + high volumeLive Trading Alerts & Screenshare at https://t.co/ooLvigTt4P #smallcaps… pic.twitter.com/dLX0ZhUwa7
— JTrader (@jtraderco) April 27, 2023
$CFRX $2.12 $2.18 $2.25 if the next low is higher we’re in a good spot!!! https://t.co/axr4eAWTnw pic.twitter.com/k35XYJqQHI
— BULLISHWIRE (@BULLISHWIRE) April 27, 2023
It is worth noting that there has been some speculation about the events that have unfolded and the underlying factors that have led to them.
We’ve observed a subset of traders that capitalize on the volatility by adopting a watchful approach towards stocks, including $CFRX, to generate quick profits.
However, it is essential to exercise caution when considering following their lead, given the high risk associated with their investment strategies and the prevailing market conditions. While we do not typically recommend emulating their investment decisions, it may be an intriguing endeavor for those willing to assume a certain level of financial risk with funds they can afford to lose.
About ContraFect Corp (NASDAQ: CFRX)
ContraFect is a company that focuses on finding new ways to treat life-threatening infections resistant to antibiotics. Antibiotic-resistant infections are responsible for an estimated 700,000 deaths each year worldwide. ContraFect is developing new medical treatments called DLAs that include lysins and amurin peptides. Lysins are antimicrobial proteins that can quickly kill target bacteria, including those in biofilms, and can work with traditional antibiotics. Amurin peptides can fight many antibiotic-resistant Gram-negative pathogens, including P. aeruginosa, Acinetobacter baumannii, and Enterobacter species. ContraFect believes that lysins and amurin peptides will effectively fight antibiotic-resistant organisms, such as MRSA and P. aeruginosa, which can cause serious infections. The company has completed a Phase 2 clinical trial for their lead lysin candidate, exebacase, designated by the FDA as a Breakthrough Therapy for treating MRSA bloodstream infections, including right-sided endocarditis, when combined with traditional antibiotics.
We will update you on CFRX when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening with CFRX.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.
Image by Sasin Tipchai from Pixabay
Wearable Devices Ltd. (NASDAQ: WLDS) Breaking Boundaries with AI
CohBar Inc. (NASDAQ: CWBR) and Morphogenesis Join Hands to Create TuHURA Biosciences
Aemetis Inc. (NASDAQ: AMTX) Pioneers Renewable Fuel Market with EPA Approval
Enveric Biosciences (NASDAQ: ENVB) Pioneering the Future of Anxiety Disorder Treatment
Immutep Limited (NASDAQ: IMMP) Immuno-oncology Breakthrough with Phase 2 Trial Combining Merck & Co’s Keytruda
-
Uncategorized6 months agoMeta Materials Inc (OTCMKTS: MMTLP) Enormous Short Position in Trouble as Next Bridge Hydrocarbons Set to Stop Trading (George Palikaras & John Brda on Corporate Action)
-
Micro Cap Insider2 years agoMedium (KOK PLAY) The Parabolic Rise of Metal Arts (OTCMKTS: MTRT)
-
Media & Technology2 years agoHealthier Choices Management Corp. (OTCMKTS: HCMC) Powerful Comeback Brewing as PMI Patent Infringement Lawsuit Moves Forward
-
Media & Technology2 years ago
AMECA Mining RM; the Rise of Southcorp Capital, Inc. (OTCMKTS: STHC)
-
Media & Technology2 years agoSNPW (Sun Pacific Holding Corp) Power Brewing: 50MW solar farm project in Durango Mexico MOU with Atlas Medrecycler 48,000 SF New Partnership Queensland Australia Solar Farm.
-
BioPharma1 year agoAsia Broadband (OTCMKTS: AABB) On the Move Northbound Since Sub $0.08 Dip as Crypto Innovator Elevates AABB Crypto Exchange & Enters the NFT Space
-
Uncategorized7 months agoMeta Materials Inc (OTCMKTS: MMTLP) Short Squeeze S-1a4 Filing Signals S1 Approval Could Be Days Away (Next Bridge Hydrocarbons Spin-Off)
-
BioPharma2 years agoHumbl Inc (OTCMKTS: HMBL) Major Reversal as Powerful Advisor Rejoins the Team & Looks to Uplist to Major Exchange
walt romaneschi
January 1, 2021 at 5:46 pm
Thank You for the info